Complementary tissue immunofluorescence assays further demonstrated an upregulation of the M1 macrophage marker CD86 and a concurrent downregulation of the M2 marker CD163 in RP-6306-treated tumor tissues (Figs. 4G, S3A). Here, CD86 is linked to neoplasm.